These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 28346313)

  • 1. Population Pharmacokinetics of Gemcitabine and dFdU in Pancreatic Cancer Patients Using an Optimal Design, Sparse Sampling Approach.
    Serdjebi C; Gattacceca F; Seitz JF; Fein F; Gagnière J; François E; Abakar-Mahamat A; Deplanque G; Rachid M; Lacarelle B; Ciccolini J; Dahan L
    Ther Drug Monit; 2017 Jun; 39(3):290-296. PubMed ID: 28346313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of gemcitabine and its metabolite in Japanese cancer patients: impact of genetic polymorphisms.
    Sugiyama E; Kaniwa N; Kim SR; Hasegawa R; Saito Y; Ueno H; Okusaka T; Ikeda M; Morizane C; Kondo S; Yamamoto N; Tamura T; Furuse J; Ishii H; Yoshida T; Saijo N; Sawada J
    Clin Pharmacokinet; 2010 Aug; 49(8):549-58. PubMed ID: 20608756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FFCD-1004 Clinical Trial: Impact of Cytidine Deaminase Activity on Clinical Outcome in Gemcitabine-Monotherapy Treated Patients.
    Serdjebi C; Gagnière J; Desramé J; Fein F; Guimbaud R; François E; André T; Seitz JF; Montérymard C; Arsene D; Volet J; Abakar-Mahamat A; Lecomte T; Guerin-Meyer V; Legoux JL; Deplanque G; Guillet P; Ciccolini J; Lepage C; Dahan L
    PLoS One; 2015; 10(8):e0135907. PubMed ID: 26308942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determinants of the interindividual variability in serum cytidine deaminase activity of patients with solid tumours.
    Cohen R; Preta LH; Joste V; Curis E; Huillard O; Jouinot A; Narjoz C; Thomas-Schoemann A; Bellesoeur A; Tiako Meyo M; Quilichini J; Desaulle D; Nicolis I; Cessot A; Vidal M; Goldwasser F; Alexandre J; Blanchet B
    Br J Clin Pharmacol; 2019 Jun; 85(6):1227-1238. PubMed ID: 30701582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative pharmacokinetics and metabolic pathway of gemcitabine during intravenous and intra-arterial delivery in unresectable pancreatic cancer patients.
    Shamseddine AI; Khalifeh MJ; Mourad FH; Chehal AA; Al-Kutoubi A; Abbas J; Habbal MZ; Malaeb LA; Bikhazi AB
    Clin Pharmacokinet; 2005; 44(9):957-67. PubMed ID: 16122282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of gemcitabine in Japanese cancer patients: the impact of a cytidine deaminase polymorphism.
    Sugiyama E; Kaniwa N; Kim SR; Kikura-Hanajiri R; Hasegawa R; Maekawa K; Saito Y; Ozawa S; Sawada J; Kamatani N; Furuse J; Ishii H; Yoshida T; Ueno H; Okusaka T; Saijo N
    J Clin Oncol; 2007 Jan; 25(1):32-42. PubMed ID: 17194903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene polymorphisms, pharmacokinetics, and hematological toxicity in advanced non-small-cell lung cancer patients receiving cisplatin/gemcitabine.
    Joerger M; Burgers JA; Baas P; Doodeman VD; Smits PH; Jansen RS; Vainchtein LD; Rosing H; Huitema AD; Beijnen JH; Schellens JH
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):25-33. PubMed ID: 21590444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of gemcitabine in a patient with end-stage renal disease: effective clearance of its main metabolite by standard hemodialysis treatment.
    Kiani A; Köhne CH; Franz T; Passauer J; Haufe T; Gross P; Ehninger G; Schleyer E
    Cancer Chemother Pharmacol; 2003 Mar; 51(3):266-70. PubMed ID: 12655447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism.
    Maring JG; Wachters FM; Slijfer M; Maurer JM; Boezen HM; Uges DR; de Vries EG; Groen HJ
    Eur J Clin Pharmacol; 2010 Jun; 66(6):611-7. PubMed ID: 20213492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SLC28A3 genotype and gemcitabine rate of infusion affect dFdCTP metabolite disposition in patients with solid tumours.
    Khatri A; Williams BW; Fisher J; Brundage RC; Gurvich VJ; Lis LG; Skubitz KM; Dudek AZ; Greeno EW; Kratzke RA; Lamba JK; Kirstein MN
    Br J Cancer; 2014 Jan; 110(2):304-12. PubMed ID: 24300978
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracellular pharmacokinetics of gemcitabine, its deaminated metabolite 2',2'-difluorodeoxyuridine and their nucleotides.
    Derissen EJB; Huitema ADR; Rosing H; Schellens JHM; Beijnen JH
    Br J Clin Pharmacol; 2018 Jun; 84(6):1279-1289. PubMed ID: 29451684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intracellular Cytidine Deaminase Regulates Gemcitabine Metabolism in Pancreatic Cancer Cell Lines.
    Bjånes TK; Jordheim LP; Schjøtt J; Kamceva T; Cros-Perrial E; Langer A; Ruiz de Garibay G; Kotopoulis S; McCormack E; Riedel B
    Drug Metab Dispos; 2020 Mar; 48(3):153-158. PubMed ID: 31871136
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intraperitoneal gemcitabine pharmacokinetics: a pilot and pharmacokinetic study in patients with advanced adenocarcinoma of the pancreas.
    Gamblin TC; Egorin MJ; Zuhowski EG; Lagattuta TF; Herscher LL; Russo A; Libutti SK; Alexander HR; Dedrick RL; Bartlett DL
    Cancer Chemother Pharmacol; 2008 Sep; 62(4):647-53. PubMed ID: 18040687
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of gemcitabine at fixed-dose rate infusion in patients with normal and impaired hepatic function.
    Felici A; Di Segni S; Milella M; Colantonio S; Sperduti I; Nuvoli B; Contestabile M; Sacconi A; Zaratti M; Citro G; Cognetti F
    Clin Pharmacokinet; 2009; 48(2):131-41. PubMed ID: 19271785
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase I pharmacokinetic study of hypoxic abdominal stop-flow perfusion with gemcitabine in patients with advanced pancreatic cancer and refractory malignant ascites.
    Kuemmerle A; Decosterd LA; Buclin T; Liénard D; Stupp R; Chassot PG; Mosimann F; Lejeune F
    Cancer Chemother Pharmacol; 2009 Jan; 63(2):331-41. PubMed ID: 18587581
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Population pharmacokinetics of gemcitabine applied to personalize the dosage used in cancer patients].
    Ramón-López A; Escudero-Ortiz V; Duart-Duart MJ; Pérez-Ruixo JJ; Valenzuela B
    Farm Hosp; 2012; 36(4):194-206. PubMed ID: 22078546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of gemcitabine and 2',2'-difluorodeoxyuridine in a patient with ascites.
    Delauter BJ; Ramanathan RK; Egorin MJ; Stover LL; Zuhowski EG; Plunkett W; Zamboni WC
    Pharmacotherapy; 2000 Oct; 20(10):1204-7. PubMed ID: 11034044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanistic Multiscale Pharmacokinetic Model for the Anticancer Drug 2',2'-difluorodeoxycytidine (Gemcitabine) in Pancreatic Cancer.
    Garcia-Cremades M; Melillo N; Troconiz IF; Magni P
    Clin Transl Sci; 2020 May; 13(3):608-617. PubMed ID: 32043298
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Homozygous CDA*3 is a major cause of life-threatening toxicities in gemcitabine-treated Japanese cancer patients.
    Ueno H; Kaniwa N; Okusaka T; Ikeda M; Morizane C; Kondo S; Sugiyama E; Kim SR; Hasegawa R; Saito Y; Yoshida T; Saijo N; Sawada J
    Br J Cancer; 2009 Mar; 100(6):870-3. PubMed ID: 19293806
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma and cerebrospinal fluid pharmacokinetics of gemcitabine after intravenous administration in nonhuman primates.
    Kerr JZ; Berg SL; Dauser R; Nuchtern J; Egorin MJ; McGuffey L; Aleksic A; Blaney S
    Cancer Chemother Pharmacol; 2001 May; 47(5):411-4. PubMed ID: 11391856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.